The DMXL1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from HeLa cells, with targeted disruption of the DMXL1 gene. This loss-of-function model eliminates the DMXL1 scaffold protein, enabling study of its roles in endolysosomal regulation. The polyclonal format avoids clonal selection bias, providing a genetically diverse background for robust functional assays.
HeLa cells are an immortalized cervical adenocarcinoma line positive for HPV18, widely used as a model for cancer cell biology. Their epithelial origin and well-characterized signaling networks make them ideal for generating gene-edited derivatives. The cancer context is particularly relevant for probing DMXL1-dependent processes that intersect with tumor metabolism and vesicular trafficking.
DMXL1 functions as a scaffold protein critical for assembling the vacuolar ATPase (V-ATPase) complex on endolysosomes. It interacts with V-ATPase subunits (ATP6V0, ATP6V1), the RAB3GAP complex, RAB GTPases, and AP-2 adaptor to regulate proton pump activity and organelle acidification. Downstream, DMXL1 influences lysosomal pH, autophagosome-lysosome fusion, and mTORC1 signaling. Disruption of DMXL1 impairs lysosomal degradation, autophagy flux, and nutrient-sensing pathways, with key markers including LAMP1, LC3, and EEA1.
In the HeLa cervical adenocarcinoma background, DMXL1 knockout provides a physiologically relevant platform to dissect the interplay between lysosomal acidification and oncogenic signaling. Cancer cells frequently upregulate V-ATPase activity to maintain pH homeostasis and support metabolic reprogramming. Disruption of DMXL1 enables detailed investigation of how impaired V-ATPase scaffolding affects mTORC1-dependent anabolism, autophagy-mediated quality control, and endocytic recycling??processes often hijacked in tumorigenesis. Moreover, because DMXL1 mutations are linked to developmental and epileptic encephalopathy, this model serves as a surrogate to study lysosomal pathophysiology that may underlie neurodevelopmental defects, while leveraging the well-characterized HeLa system. The polyclonal nature introduces heterogeneity that better reflects intratumoral variability, enhancing the translational utility of pharmacological studies.
Researchers can employ Western blotting to confirm DMXL1 depletion and assess V-ATPase subunit levels. LysoTracker staining quantifies lysosomal pH, while immunofluorescence for LAMP1 and LC3 visualizes lysosomes and autophagosomes. Autophagy flux is measured by LC3-II accumulation under bafilomycin A1 treatment, and mTORC1 activity is evaluated via phospho-S6K immunoblotting. Additional functional assays, including cell migration and invasion tests, probe the role of lysosomal acidification in tumor motility. This model is suitable for V-ATPase modulator screening and structure-function studies. For product inquiries, please contact Ascent Research.
